Cristiana Pires

CEO at Asgard Tx

Speaker

Cristiana Pires is Chief Executive Officer and scientific co-founder of Asgard Therapeutics, a pre-clinical stage company developing in-vivo direct reprogramming approaches for cancer immunotherapy. As CEO, Dr. Pires spearheads Asgard’s mission to pioneer off-the-shelf therapies capable of recreating functional immune cells within the patient´s body, overcoming the manufacturing and logistic hurdles of traditional cell therapies.

Asgard’s lead program, AT-108, is a first-in-class, off-the-shelf approach that converts tumor cells into highly immunogenic antigen presenting cells, kick-starting systemic and personalized anti-tumor responses. AT-108 is an intra-tumoral gene therapy vector that delivers proprietary reprogramming factors to solid tumors, with strong PoC data published recently in the journal Science. Under Cristiana’s leadership, the company secured a total of EUR 36 million from top VC investors and corporate funds to advance AT-108 to FIH trials and further develop the company’s pipeline.